Gelonghui, March 14, 丨 Dongyang Pharmaceutical (1558.HK) bucked the trend in the intraday market and rose more than 9%. The highest price of HK$888 hit a 20-month high. The turnover clearly increased to HK$59.85 million, with a total market capitalization of HK$7.4 billion. Damoyudong Yangguang Pharmaceutical “increased its holdings” rating, raising the target price by 64% to HK$12. The valuation is attractive. Recent data from the US Centers for Disease Control and Prevention (CDC) shows that H1N1, worsening influenza, has reappeared. As the main producer of the influenza antiviral drug “oseltamivir” in the mainland, there is a strong correlation between the company's profit and stock price performance and incidence data. The company's sharp stock-outs and increased production operations suggest that this year will see breakthrough sales growth.